Edwards Lifesciences, CareFusion Announce Collaboration Agreement

Companies to Establish Interoperability between Hemodynamic Monitoring Systems and Infusion Devices

Oct 26, 2015

SAN DIEGO and IRVINE, Calif., October 23, 2015 – Edwards Lifesciences and CareFusion, a BD company, today announced a collaboration agreement to enable interoperability between patient hemodynamic management and IV fluid administration.

The collaboration will focus on hydration for moderate to high risk surgical patients using Edwards Lifesciences' advanced hemodynamic monitoring systems and fluid management algorithms and CareFusion Alaris® Infusion Systems. The companies will explore reported correlations between appropriately hydrated patients undergoing surgery and improved post-surgical outcomes, including enabling patients to leave the hospital sooner and with fewer complications.

"We are proud to continue our decades-long partnership with physicians to advance patient care, and offer an integrated solution to patient management. We are focused on providing clinicians with innovative technologies that enable them to monitor a patient's fluid levels before, during and after surgery, and implement care strategies to aid in their recovery. We look forward to working closely with CareFusion to advance patient care," said Katie Szyman, Edwards' corporate vice president, critical care and vascular.

J.C. Kyrillos, world-wide vice president and general manager of Infusion Solutions for BD, said "This collaboration builds on our history of innovation in patient monitoring infusion solutions and the investments we've made in our interoperability platform that integrates the Alaris Infusion System to HIT systems. We are excited to extend that interoperability capability to integration with patient monitoring. Our vision is to create interoperability with many different types of systems and devices to help improve the patient care, efficiency and cost of IV therapy."

Maxime Cannesson, MD, PhD added, "It's exciting to see leading companies like Edwards and CareFusion partnering with clinicians to drive meaningful innovations that decrease variability in the way care is provided, with the goal of improving patients' outcomes."

The companies have entered into to a broad-based collaboration to investigate multiple applications of their respective technologies. Specific terms of the agreement were not disclosed.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com.

About BD

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

For more information on BD, please visit bd.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements made by Katie Szyman, J.C. Kyrillos and Dr. Maxime Cannesson and statements regarding the potential need for, and features and benefits of, a system developed by Edwards and CareFusion. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unanticipated delays or outcomes of the collaboration and unanticipated clinical outcomes following longer term experience. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2014. These filings, along with important safety information about our products, may be found at www.edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

CareFusion Corporation

Troy Kirkpatrick

858 617 2361
Email Troy

Back to News Releases

1 Nouruzi-Sedeh P. et al. Anethesiology, 2009; 110(1): 32-37.

2 Zaouter C. et al. BJA, 114(2): 181-183.

3 DuCanto J.C et al. Anesthesiology News, 2013; Guide to Airway Management: Special report.

4 White P.F. et al. Anesthesiology News, 2011; Video Laryngoscopy: A debate.

5 Hodd J. et al. ASA, 2010; The A.P. Advance laryngoscope V Glidescope in High-fidelity simulator.v

6 Zampone S. et al. Anaesthesiology Clinical Pharm, 2015; 31(1): 134-136.

7 Butchart A.G. et al. Acad Emerg Med, Jul 2011; 18(7): 692-698.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.